Document is current

Article History

Accepted: 3 February 2025

First Online: 12 March 2025

Declarations

:

: This study was sponsored by GSK (Study identifier VEO-000505). Support for third-party writing assistance for this article, provided by Isabel Haber, Costello Medical, USA was funded by GSK in accordance with Good Publication Practice 2022 guidelines ().

: Hiral Anil Shah is an employee and shareholder of GSK. Ginita Jutlla received consulting fees from GSK. Oscar Herrera-Restrepo is an employee and shareholder of GSK. Jonathan Graham is an employee of RTI Health Solutions, which received payment for this study from GSK. Mei Grace is an employee of RTI Health Solutions, which received payment for this study from GSK. Shah Alam Khan was an employee of HEOR at the time of this study, which received payment for this study from GSK. Elise Kuylen is an employee and shareholder of GSK. Shahina Begum is an employee of GSK. Frederik Verelst is an employee and shareholder of GSK. Zeki Kocaata is an employee and shareholder of GSK.

: Not applicable.

: Not applicable.

: Not applicable.

: The datasets generated and/or analysed during the current study are available from the corresponding author upon reasonable request.

: Not applicable.

: Substantial contributions to the study conception and design: HAS, GJ, OHR, JG, MG, SAK, EK, SB, FV, ZK; substantial contributions to the analysis and interpretation of the data: HAS, GJ, OHR, JG, MG, SAK, EK, SB, FV, ZK; drafting the article or revising it critically for important intellectual content: HAS, GJ, OHR, JG, MG, SAK, EK, SB, FV, ZK; final approval of the version of the article to be published: HAS, GJ, OHR, JG, MG, SAK, EK, SB, FV, ZK.

: The data were previously presented at the European Society for Paediatric Infectious Diseases (ESPID) 2024 annual meeting.